Transaction DateRecipientSharesTypePriceValue
14th December 2020Lindsay A Md Rosenwald100,000Open or private purchase$2.66$266,000.00
22nd September 2020Robyn Hunter28,450Open or private sale$4.38$124,611.00
26th August 2020Malcolm Hoenlein16,667Open or private purchase$18.00$300,006.00
26th August 2020Lindsay A Md Rosenwald52,500Open or private purchase$18.00$945,000.00
14th July 2020Lindsay A Md Rosenwald16,611Grant/award etc.$0.00
14th July 2020Michael S Weiss16,611Grant/award etc.$0.00
22nd June 2020Michael S Weiss1,556,029Grant/award etc.$0.00
5th June 2020Michael S Weiss24,390Grant/award etc.$0.00
5th June 2020Lindsay A Md Rosenwald24,390Grant/award etc.$0.00
3rd June 2020Eric K Rowinsky890Grant/award etc.$0.00
Fortress Biotech
Fortress Biotech logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National. The National segment consists of National Holdings Corporation.

Ticker: FBIO
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1429260
Employees: 88
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $183 M (33%)
Inventory, Net: $1 M (41%)
Assets, Current: $200 M (27%)
Property, Plant and Equipment, Net: $12 M (0%)
Other Assets, Noncurrent: $1 M (16%)
Assets: $269 M (18%)
Accrued Liabilities, Current: $21 M (-16%)
Liabilities, Current: $57 M (24%)
Other Liabilities, Noncurrent: $7 M (0%)
Liabilities: $152 M (-1%)
Common Stock, Value, Issued: $86 Th (16%)
Common Stock, Shares, Issued: $86 M (16%)
Retained Earnings (Accumulated Deficit): $462 M (5%)
Stockholders' Equity (Parent): $60 M (130%)
Liabilities and Equity: $269 M (18%)
Cost of Revenue: $3 M (-54%)
Operating Income/Loss: $25 M (-45%)
Other Income, net: $3 M (-45%)